GleamWall
中文EN

HALO HALOZYME THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1159036 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY45.0%
TTM net income YoY-18.5%
TTM EPS YoY-15.6%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR24.1%

Margins

Gross margin82.3%
Operating margin37.4%
Net margin26.9%
FCF margin49.1%
EBITDA margin38.3%

Returns

ROE216.4%
ROA17.0%
ROIC (approx.)26.6%
Asset turnover0.63x

Leverage & solvency

Liabilities / assets101.6%
Debt / equity—
Current ratio3.88x
Interest coverage30.58x

Cash quality & payout

Operating cash flow / net income1.85x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$492.97M$481.00M$376.71M$451.77M$354.26M$325.72M$264.86M$298.01M
Cost of revenue$82.47M$79.17M$79.24M$78.77M$55.24M$46.36M$48.40M$42.05M
Gross profit$410.50M$401.83M$297.47M$373.00M$299.02M$279.36M$216.46M$255.95M
R&D expense$27.78M$27.66M$25.56M$31.90M$17.25M$17.54M$14.80M$20.44M
SG&A expense$58.24M$57.00M$57.88M$77.03M$46.09M$41.61M$42.36M$42.25M
Operating income$294.97M$287.65M$184.52M-$92.89M$217.92M$202.44M$141.53M$175.50M
Interest expense$6.04M$5.59M$5.51M$4.91M$4.30M$4.39M$4.53M$4.54M
Pretax income$290.63M$284.90M$180.33M-$100.85M$218.96M$204.94M$143.83M$178.21M
Income tax$43.58M$54.99M$30.28M$40.74M$43.73M$39.78M$25.73M$41.20M
Net income$247.05M$229.91M$150.05M-$141.59M$175.22M$165.16M$118.09M$137.01M
EBITDA$299.67M$292.15M$188.74M-$89.59M$220.62M$205.14M$144.22M$178.15M
EPS (basic)2.171.961.27—1.491.360.96—
EPS (diluted)2.011.901.22—1.431.330.93—
Weighted avg. shares (diluted)122.61M121.22M122.88M—122.33M124.16M126.64M—
Balance sheet
Cash & equivalents$1.03B$163.14M$309.75M$133.82M$419.67M$61.86M$176.33M$115.85M
Receivables$518.59M$453.33M$457.99M$426.27M$343.54M$315.07M$304.02M$288.20M
Inventory$132.61M$137.13M$155.47M$176.47M$185.80M$181.50M$164.87M$141.86M
Current assets$1.85B$933.02M$1.00B$825.21M$1.33B$1.12B$1.26B$1.09B
PP&E, net$51.20M$49.76M$46.93M$44.44M$40.58M$39.60M$40.22M$40.86M
Goodwill$581.73M$581.73M$582.32M$580.36M$416.82M$416.82M$416.82M$416.82M
Intangibles$892.93M$922.44M$951.96M$981.47M$348.54M$366.31M$384.07M$401.83M
Total assets$3.47B$2.58B$2.67B$2.53B$2.22B$2.05B$2.20B$2.06B
Current liabilities$476.09M$344.44M$363.21M$177.09M$837.23M$134.28M$150.38M$139.10M
Short-term debt$305.61M$208.97M$208.74M$0$710.68M——$0
Long-term debt$2.94B$1.94B$1.94B$2.14B$800.07M$1.51B$1.51B$1.51B
Total debt$3.25B$2.15B$2.14B$2.14B$1.51B$1.51B$1.51B$1.51B
Total liabilities$3.53B$2.43B$2.45B$2.48B$1.72B$1.72B$1.71B$1.70B
Shareholders' equity-$55.24M$143.54M$219.64M$48.81M$503.92M$332.75M$482.27M$363.82M
Net debt$2.22B$1.98B$1.83B$2.01B$1.09B$1.45B$1.33B$1.39B
Shares outstanding113.94M114.04M118.52M117.78M117.52M117.62M123.17M123.14M
Cash flow statement
Operating cash flow$258.27M$240.89M$180.08M$219.03M$178.60M$99.71M$154.22M$178.47M
Capital expenditure$3.05M$4.17M$3.74M$1.43M$3.03M$1.56M$950,000$3.05M
Free cash flow$255.22M$236.72M$176.34M$217.60M$175.57M$98.15M$153.27M$175.41M
Investing cash flow$20.95M-$62.66M-$2.88M-$741.79M$201.61M$84.79M-$90.42M$29.48M
Financing cash flow$587.64M-$326.25M-$1.61M$239.51M-$22.40M-$298.97M-$3.32M-$246.41M
Depreciation & amortization$4.70M$4.50M$4.22M$3.30M$2.70M$2.70M$2.69M$2.65M
Stock-based compensation$16.80M$17.70M$16.64M$16.57M$12.16M$12.16M$10.67M$11.46M
Share buybacks$67.27M——$0$38.88M——$250.00M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.